Nicolet Advisory Services LLC Boosts Holdings in Bio-Techne Co. (NASDAQ:TECH)

Nicolet Advisory Services LLC increased its stake in shares of Bio-Techne Co. (NASDAQ:TECH) by 7.9% in the 3rd quarter, Holdings Channel reports. The firm owned 6,071 shares of the biotechnology company’s stock after purchasing an additional 443 shares during the period. Nicolet Advisory Services LLC’s holdings in Bio-Techne were worth $449,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TECH. Empirical Finance LLC increased its stake in Bio-Techne by 4.1% during the 3rd quarter. Empirical Finance LLC now owns 4,080 shares of the biotechnology company’s stock worth $326,000 after buying an additional 160 shares in the last quarter. First City Capital Management Inc. lifted its holdings in Bio-Techne by 6.2% in the 1st quarter. First City Capital Management Inc. now owns 3,185 shares of the biotechnology company’s stock valued at $224,000 after purchasing an additional 185 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its stake in Bio-Techne by 3.9% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,333 shares of the biotechnology company’s stock worth $426,000 after purchasing an additional 200 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Bio-Techne by 12.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,917 shares of the biotechnology company’s stock worth $137,000 after buying an additional 205 shares in the last quarter. Finally, Mather Group LLC. raised its position in shares of Bio-Techne by 51.5% in the third quarter. Mather Group LLC. now owns 612 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 208 shares during the last quarter. 98.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TECH has been the topic of a number of recent research reports. StockNews.com upgraded shares of Bio-Techne from a “hold” rating to a “buy” rating in a research report on Tuesday, November 12th. Scotiabank raised their target price on shares of Bio-Techne from $83.00 to $88.00 and gave the stock a “sector outperform” rating in a research note on Thursday, October 31st. Robert W. Baird upped their price target on Bio-Techne from $82.00 to $84.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Benchmark reaffirmed a “buy” rating and issued a $95.00 price target on shares of Bio-Techne in a report on Tuesday, August 13th. Finally, Royal Bank of Canada lowered their price objective on Bio-Techne from $72.00 to $70.00 and set a “sector perform” rating on the stock in a research note on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $81.78.

Bio-Techne Trading Up 0.3 %

Shares of Bio-Techne stock opened at $71.28 on Friday. Bio-Techne Co. has a fifty-two week low of $61.16 and a fifty-two week high of $85.57. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.26 and a current ratio of 4.56. The firm has a market capitalization of $11.33 billion, a price-to-earnings ratio of 75.83, a PEG ratio of 5.19 and a beta of 1.28. The stock has a 50 day moving average of $73.77 and a 200 day moving average of $75.25.

Bio-Techne (NASDAQ:TECH) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.04. The firm had revenue of $289.46 million during the quarter, compared to the consensus estimate of $280.22 million. Bio-Techne had a return on equity of 12.76% and a net margin of 12.86%. The company’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period last year, the company earned $0.35 EPS. As a group, research analysts predict that Bio-Techne Co. will post 1.68 earnings per share for the current year.

Bio-Techne Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 22nd. Stockholders of record on Monday, November 11th were issued a $0.08 dividend. The ex-dividend date was Friday, November 8th. This represents a $0.32 annualized dividend and a dividend yield of 0.45%. Bio-Techne’s dividend payout ratio is currently 34.04%.

Bio-Techne Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.